MA65559B1 - Composition de cannabinoïdes et son application dans la préparation d'un médicament pour le traitement de maladies neurodégénératives telles que la maladie de parkinson et la maladie d'alzheimer - Google Patents
Composition de cannabinoïdes et son application dans la préparation d'un médicament pour le traitement de maladies neurodégénératives telles que la maladie de parkinson et la maladie d'alzheimerInfo
- Publication number
- MA65559B1 MA65559B1 MA65559A MA65559A MA65559B1 MA 65559 B1 MA65559 B1 MA 65559B1 MA 65559 A MA65559 A MA 65559A MA 65559 A MA65559 A MA 65559A MA 65559 B1 MA65559 B1 MA 65559B1
- Authority
- MA
- Morocco
- Prior art keywords
- maladie
- composition
- drug
- treatment
- neurodegenerative diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une composition de cannabinoïdes et une application de celle-ci dans la préparation d'un médicament pour le traitement de maladies neurodégénératives, pour une utilisation dans la résolution des problèmes existants d'effets secondaires importants et de moindre efficacité thérapeutique après une utilisation de longue durée d'un médicament pour le traitement de maladies neurodégénératives. La composition de cannabinoïdes comprend du cannabidiol et du cannabigérol qui sont dans un rapport massique de 1: 1 à 1 : 10 ou 1 : 0,3 à 1 : 0,5 ou 1 : 0,5 à 1 : 0,7 ou 1 : 0,7 à 1 : 1. Selon la présente invention, en utilisant une méthode expérimentale pour induire la différenciation de fibroblastes en cellules nerveuses dopaminergiques pour observer les morphologies et le nombre de cellules après l'induction de la différenciation cellulaire et pour détecter un niveau d'expression de facteurs associés à DA, et pour cribler les effets de différents cannabinoïdes communs et des combinaisons de ceux-ci sur l'induction de la différenciation de fibroblastes en neurones dopaminergiques, il a été découvert qu'une combinaison CBD + CBG a des effets optimaux sur l'amélioration de la capacité de survie et de la capacité de sécrétion de dopamine des neurones dopaminergiques, ne contient pas la substance addictive THC et réduit ainsi considérablement les effets secondaires d'un médicament, et peut être utilisée pour préparer un médicament pour le traitement de maladies neurodégénératives.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110916566.9A CN113368086B (zh) | 2021-08-11 | 2021-08-11 | 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用 |
| PCT/CN2021/133379 WO2023015772A1 (fr) | 2021-08-11 | 2021-11-26 | Composition de cannabinoïdes et son application dans la préparation d'un médicament pour le traitement de maladies neurodégénératives telles que la maladie de parkinson et la maladie d'alzheimer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA65559A1 MA65559A1 (fr) | 2025-02-28 |
| MA65559B1 true MA65559B1 (fr) | 2025-12-31 |
Family
ID=77576733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA65559A MA65559B1 (fr) | 2021-08-11 | 2021-11-23 | Composition de cannabinoïdes et son application dans la préparation d'un médicament pour le traitement de maladies neurodégénératives telles que la maladie de parkinson et la maladie d'alzheimer |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11497719B1 (fr) |
| EP (1) | EP4205732B1 (fr) |
| JP (1) | JP7220818B1 (fr) |
| KR (1) | KR102623984B1 (fr) |
| CN (1) | CN113368086B (fr) |
| AU (1) | AU2021459955B2 (fr) |
| CA (1) | CA3192406C (fr) |
| DK (1) | DK4205732T3 (fr) |
| ES (1) | ES3062607T3 (fr) |
| FI (1) | FI4205732T3 (fr) |
| HR (1) | HRP20260264T1 (fr) |
| IL (1) | IL302085A (fr) |
| LT (1) | LT4205732T (fr) |
| MA (1) | MA65559B1 (fr) |
| MD (1) | MD20250033A2 (fr) |
| MX (1) | MX2024001818A (fr) |
| NZ (1) | NZ807398A (fr) |
| PL (1) | PL4205732T3 (fr) |
| PT (1) | PT4205732T (fr) |
| RS (1) | RS67760B1 (fr) |
| SI (1) | SI4205732T1 (fr) |
| SM (1) | SMT202600078T1 (fr) |
| WO (1) | WO2023015772A1 (fr) |
| ZA (1) | ZA202400378B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368086B (zh) * | 2021-08-11 | 2021-12-03 | 龙麻(上海)医药研发有限责任公司 | 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用 |
| KR20240036952A (ko) * | 2022-09-14 | 2024-03-21 | 주식회사 네오켄바이오 | 칸나비노이드를 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물 및 이의 용도 |
| US20240350592A1 (en) * | 2023-04-12 | 2024-10-24 | Xygenyx Inc. | Composition and methods of treatment using synergistically-enhanced supplementation |
| WO2026018132A1 (fr) * | 2024-07-16 | 2026-01-22 | Buzzelet Development And Technologies Ltd. | Compositions contenant des cannabinoïdes |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107095302A (zh) * | 2017-05-09 | 2017-08-29 | 何宗迅 | 大麻素类混合物及其在食品工业中的应用 |
| CN109963590A (zh) * | 2016-09-02 | 2019-07-02 | 加利福尼亚大学董事会 | 涉及白介素-6受体α结合单链可变片段的方法和组合物 |
| CN113116869A (zh) * | 2019-12-31 | 2021-07-16 | 汉义生物科技（北京）有限公司 | 一种预防和/或治疗抑郁的组合物 |
| US20230218567A1 (en) * | 2019-06-26 | 2023-07-13 | RCR BioPharma | Compound and method for treating diseases and disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2434312B (en) * | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
| ES2359168T3 (es) * | 2007-10-02 | 2011-05-19 | Vivacell Biotechnology España S.L. | Composición que comprende cannabinoides no psicotrópicos para el tratamiento de enfermedades antiinflamatorias. |
| GB2527590A (en) * | 2014-06-27 | 2015-12-30 | Otsuka Pharma Co Ltd | Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer |
| CN109963595B (zh) * | 2016-10-11 | 2023-02-03 | Gbs全球生物制药公司 | 用于治疗神经退行性疾病的含有大麻素的复合混合物 |
| GB2559774B (en) * | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| EP3589129A4 (fr) * | 2017-03-01 | 2020-11-25 | Canopy Growth Corporation | Compositions sélectionnées de manière ciblée comportant des cannabinoïdes purifiés et/ou des terpènes purifiés |
| US12324789B2 (en) * | 2017-08-28 | 2025-06-10 | Apirx Pharmaceutical Usa, Llc | Method to treat psoriasis |
| US11484510B2 (en) * | 2017-08-28 | 2022-11-01 | Apirx Pharmaceutical Usa, Llc | Method to treat vitiligo |
| WO2022043961A1 (fr) * | 2020-08-31 | 2022-03-03 | Nelson Mandela University | Associations de cannabinoïdes et leur utilisation dans le traitement du cancer |
| GB202101732D0 (en) * | 2021-02-08 | 2021-03-24 | Tts Pharma Ltd | A cannabinoid mixture |
| CN113368086B (zh) * | 2021-08-11 | 2021-12-03 | 龙麻(上海)医药研发有限责任公司 | 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用 |
| EP4408404A4 (fr) * | 2021-09-28 | 2025-10-29 | Gbs Global Biopharma Inc | Formulations contenant des cannabinoïdes pour des troubles du mouvement parkinsoniens |
-
2021
- 2021-08-11 CN CN202110916566.9A patent/CN113368086B/zh active Active
- 2021-11-23 MA MA65559A patent/MA65559B1/fr unknown
- 2021-11-26 PL PL21953377.5T patent/PL4205732T3/pl unknown
- 2021-11-26 ES ES21953377T patent/ES3062607T3/es active Active
- 2021-11-26 RS RS20260204A patent/RS67760B1/sr unknown
- 2021-11-26 FI FIEP21953377.5T patent/FI4205732T3/fi active
- 2021-11-26 PT PT219533775T patent/PT4205732T/pt unknown
- 2021-11-26 MD MDA20250033A patent/MD20250033A2/ro unknown
- 2021-11-26 MX MX2024001818A patent/MX2024001818A/es unknown
- 2021-11-26 SM SM20260078T patent/SMT202600078T1/it unknown
- 2021-11-26 AU AU2021459955A patent/AU2021459955B2/en active Active
- 2021-11-26 WO PCT/CN2021/133379 patent/WO2023015772A1/fr not_active Ceased
- 2021-11-26 EP EP21953377.5A patent/EP4205732B1/fr active Active
- 2021-11-26 KR KR1020237011823A patent/KR102623984B1/ko active Active
- 2021-11-26 NZ NZ807398A patent/NZ807398A/en unknown
- 2021-11-26 HR HRP20260264TT patent/HRP20260264T1/hr unknown
- 2021-11-26 IL IL302085A patent/IL302085A/en unknown
- 2021-11-26 LT LTEPPCT/CN2021/133379T patent/LT4205732T/lt unknown
- 2021-11-26 DK DK21953377.5T patent/DK4205732T3/da active
- 2021-11-26 SI SI202130403T patent/SI4205732T1/sl unknown
- 2021-11-26 CA CA3192406A patent/CA3192406C/fr active Active
-
2022
- 2022-01-27 US US17/586,304 patent/US11497719B1/en active Active
- 2022-02-02 JP JP2022015041A patent/JP7220818B1/ja active Active
-
2024
- 2024-01-10 ZA ZA2024/00378A patent/ZA202400378B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109963590A (zh) * | 2016-09-02 | 2019-07-02 | 加利福尼亚大学董事会 | 涉及白介素-6受体α结合单链可变片段的方法和组合物 |
| CN107095302A (zh) * | 2017-05-09 | 2017-08-29 | 何宗迅 | 大麻素类混合物及其在食品工业中的应用 |
| US20230218567A1 (en) * | 2019-06-26 | 2023-07-13 | RCR BioPharma | Compound and method for treating diseases and disorders |
| CN113116869A (zh) * | 2019-12-31 | 2021-07-16 | 汉义生物科技（北京）有限公司 | 一种预防和/或治疗抑郁的组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113368086B (zh) | 2021-12-03 |
| MD20250033A2 (ro) | 2025-08-31 |
| IL302085A (en) | 2023-06-01 |
| CN113368086A (zh) | 2021-09-10 |
| ZA202400378B (en) | 2024-03-27 |
| KR20230123010A (ko) | 2023-08-22 |
| PT4205732T (pt) | 2026-02-24 |
| MA65559A1 (fr) | 2025-02-28 |
| NZ807398A (en) | 2024-05-31 |
| RS67760B1 (sr) | 2026-03-31 |
| LT4205732T (lt) | 2026-03-25 |
| HRP20260264T1 (hr) | 2026-04-10 |
| FI4205732T3 (fi) | 2026-03-12 |
| EP4205732A1 (fr) | 2023-07-05 |
| WO2023015772A1 (fr) | 2023-02-16 |
| CA3192406C (fr) | 2024-04-09 |
| US11497719B1 (en) | 2022-11-15 |
| JP7220818B1 (ja) | 2023-02-10 |
| MX2024001818A (es) | 2024-03-06 |
| SI4205732T1 (sl) | 2026-04-30 |
| AU2021459955A1 (en) | 2023-04-13 |
| KR102623984B1 (ko) | 2024-01-11 |
| DK4205732T3 (da) | 2026-02-23 |
| JP2023026291A (ja) | 2023-02-24 |
| PL4205732T3 (pl) | 2026-04-07 |
| EP4205732B1 (fr) | 2026-01-28 |
| AU2021459955B2 (en) | 2023-09-14 |
| ES3062607T3 (en) | 2026-04-13 |
| SMT202600078T1 (it) | 2026-03-09 |
| CA3192406A1 (fr) | 2023-02-16 |
| EP4205732A4 (fr) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA65559B1 (fr) | Composition de cannabinoïdes et son application dans la préparation d'un médicament pour le traitement de maladies neurodégénératives telles que la maladie de parkinson et la maladie d'alzheimer | |
| Merayo-Lloves et al. | Safety and efficacy of autologous plasma rich in growth factors eye drops for the treatment of evaporative dry eye | |
| Mannelli et al. | Involvement of α7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation | |
| Umbricht et al. | Risperidone: efficacy and safety | |
| Merayo-Lloves et al. | Autologous plasma rich in growth factors eyedrops in refractory cases of ocular surface disorders | |
| Riedel et al. | Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms | |
| CA2956919C (fr) | Methode de traitement des troubles cognitifs ou affectifs associes a la radiotherapie et a la chimiotherapie au moyen de cannabinoides | |
| Yang et al. | Alpha tocopherol treatment reduces the expression of Nogo-A and NgR in rat brain after traumatic brain injury | |
| Asl et al. | Chitosan-coated Selenium nanoparticles enhance the efficiency of stem cells in the neuroprotection of streptozotocin-induced neurotoxicity in male rats. | |
| Guo et al. | Therapeutic effect of vinorine on sciatic nerve injured rat | |
| Wu et al. | Pyroptosis in neurodegenerative diseases: from bench to bedside | |
| Xia et al. | Human mesenchymal stem cells improve the neurodegeneration of femoral nerve in a diabetic foot ulceration rats | |
| JP2021505650A (ja) | 眼用薬物製剤及びその使用 | |
| Salehi et al. | Evaluation of caffeic acid mucoadhesive tablets on minor recurrent aphthous stomatitis: a randomized, double-blind, placebo-controlled clinical trial | |
| Bhatia et al. | Topical phenytoin suspension and normal saline in the treatment of leprosy trophic ulcers: a randomized, double‐blind, comparative study | |
| Wang et al. | Oxytocin‐loaded hydrogel promotes cartilage regeneration and regulates microenvironment | |
| Li et al. | In-situ electrospinning dressings loaded with kaempferol for reducing MMP9 to promote diabetic ulcer healing | |
| Liu et al. | Ginsenoside Rb1 ameliorates hippocampal neuroinflammation in rats after intracerebral hemorrhage by inactivating the TLR4/NF-kB pathway | |
| Siahpoosh et al. | Effect of grape seed on quality of life in multiple sclerosis patients. | |
| Nagańska et al. | Neuroprotective effect of erythropoietin in amyotrophic lateral sclerosis (ALS) model in vitro. Ultrastructural study | |
| Guo et al. | Celastrol Activates SIRT1/PGC-1α/Nrf2 Axis to Inhibit Oxidative Damage for Subconjunctival Fibrosis Alleviation | |
| Kalangara et al. | Treatment of ocular pain not responsive to traditional dry eye disease treatments | |
| CN118252795A (zh) | 人参皂苷滴眼液、其制备方法和应用 | |
| Azzahra et al. | Cytotoxicity of turmeric extract (Curcuma longa linn.) on BHK21 fibroblast cells | |
| NZ540257A (en) | Cognitive abilities improving agent obtained from Pinus bark |